Clinical Pharmacology

Support consumer access to specialty medications through value-based insurance designThe driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
NIH partners with industry to find best biological targets of diseaseThe National Institutes of Health, FDA, 10 biopharmaceutical companies, the Pharmaceutical Research and Manufacturers of America, and several nonprofit organizations have launched an unprecedented public/private partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.
Stricter bioequivalence rules may be needed for generic antiepilepsy treatments

Advertisement

Future of dermatologic innovation has bright spotsWhile government funds for research in dermatology and other medical specialties seems to be dwindling, there are forces at work that could help to pick up at least part of the slack.
FDA approves new once-daily treatment option for HIVDolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen.
Bariatric surgery affects postoperative warfarin dosingA small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.

Advertisement

FDA approves 4PCC for acute major bleedingCSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.

Advertisement

Advertisement